LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study. / Iversen, P; Rose, C; Stage, J G; Iversen, H G; Hansen, R I; Hvidt, V; Mogensen, P; Pedersen, T; Hansen, J B.

I: Scandinavian Journal of Urology and Nephrology, Bind 23, Nr. 3, 1989, s. 177-83.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Iversen, P, Rose, C, Stage, JG, Iversen, HG, Hansen, RI, Hvidt, V, Mogensen, P, Pedersen, T & Hansen, JB 1989, 'LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study', Scandinavian Journal of Urology and Nephrology, bind 23, nr. 3, s. 177-83.

APA

Iversen, P., Rose, C., Stage, J. G., Iversen, H. G., Hansen, R. I., Hvidt, V., Mogensen, P., Pedersen, T., & Hansen, J. B. (1989). LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study. Scandinavian Journal of Urology and Nephrology, 23(3), 177-83.

Vancouver

Iversen P, Rose C, Stage JG, Iversen HG, Hansen RI, Hvidt V o.a. LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study. Scandinavian Journal of Urology and Nephrology. 1989;23(3):177-83.

Author

Iversen, P ; Rose, C ; Stage, J G ; Iversen, H G ; Hansen, R I ; Hvidt, V ; Mogensen, P ; Pedersen, T ; Hansen, J B. / LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study. I: Scandinavian Journal of Urology and Nephrology. 1989 ; Bind 23, Nr. 3. s. 177-83.

Bibtex

@article{001bad581ed54eafab78839900e6286f,
title = "LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study",
abstract = "An LHRH agonist, Zoladex, was employed as a monthly depot in 56 previously untreated patients with advanced carcinoma of the prostate. Of 53 evaluable patients, 27 achieved partial remission and 7 were stable. Median duration of response was 10 months. A favorable subjective response was attained in 68% of the patients. During treatment, serum testosterone was in the castrate range in all patients except five. Possible explanations for this escape phenomenon are discussed. No toxicity was observed and treatment was well tolerated in all patients. Thirty-two patients underwent bilateral orchiectomy following treatment failure of Zoladex. In one patient partial remission according to protocol criteria was recorded. Treatment with LHRH agonists seems safe and may serve as an alternative to conventional hormonal treatment of advanced carcinoma of the prostate.",
author = "P Iversen and C Rose and Stage, {J G} and Iversen, {H G} and Hansen, {R I} and V Hvidt and P Mogensen and T Pedersen and Hansen, {J B}",
year = "1989",
language = "English",
volume = "23",
pages = "177--83",
journal = "Scandinavian Journal of Urology",
issn = "2168-1805",
publisher = "Taylor & Francis",
number = "3",

}

RIS

TY - JOUR

T1 - LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study

AU - Iversen, P

AU - Rose, C

AU - Stage, J G

AU - Iversen, H G

AU - Hansen, R I

AU - Hvidt, V

AU - Mogensen, P

AU - Pedersen, T

AU - Hansen, J B

PY - 1989

Y1 - 1989

N2 - An LHRH agonist, Zoladex, was employed as a monthly depot in 56 previously untreated patients with advanced carcinoma of the prostate. Of 53 evaluable patients, 27 achieved partial remission and 7 were stable. Median duration of response was 10 months. A favorable subjective response was attained in 68% of the patients. During treatment, serum testosterone was in the castrate range in all patients except five. Possible explanations for this escape phenomenon are discussed. No toxicity was observed and treatment was well tolerated in all patients. Thirty-two patients underwent bilateral orchiectomy following treatment failure of Zoladex. In one patient partial remission according to protocol criteria was recorded. Treatment with LHRH agonists seems safe and may serve as an alternative to conventional hormonal treatment of advanced carcinoma of the prostate.

AB - An LHRH agonist, Zoladex, was employed as a monthly depot in 56 previously untreated patients with advanced carcinoma of the prostate. Of 53 evaluable patients, 27 achieved partial remission and 7 were stable. Median duration of response was 10 months. A favorable subjective response was attained in 68% of the patients. During treatment, serum testosterone was in the castrate range in all patients except five. Possible explanations for this escape phenomenon are discussed. No toxicity was observed and treatment was well tolerated in all patients. Thirty-two patients underwent bilateral orchiectomy following treatment failure of Zoladex. In one patient partial remission according to protocol criteria was recorded. Treatment with LHRH agonists seems safe and may serve as an alternative to conventional hormonal treatment of advanced carcinoma of the prostate.

M3 - Journal article

VL - 23

SP - 177

EP - 183

JO - Scandinavian Journal of Urology

JF - Scandinavian Journal of Urology

SN - 2168-1805

IS - 3

ER -

ID: 48470433